These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11769116)

  • 1. The evaluation and management of dyslipidemia in HIV-infected patients.
    Fichtenbaum CJ
    AIDS Clin Care; 2001 Dec; 13(12):113-7, 120. PubMed ID: 11769116
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
    Dubé MP; Sprecher D; Henry WK; Aberg JA; Torriani FJ; Hodis HN; Schouten J; Levin J; Myers G; Zackin R; Nevin T; Currier JS;
    Clin Infect Dis; 2000 Nov; 31(5):1216-24. PubMed ID: 11073755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
    Aberg JA
    Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing dyslipidemia in adults with diabetes.
    Haffner SM
    Manag Care; 2003 Sep; 12(9 Suppl):10-5. PubMed ID: 14535130
    [No Abstract]   [Full Text] [Related]  

  • 5. Coronary heart disease in HIV-infected persons.
    Glesby MJ
    AIDS Read; 2003 Apr; 13(4 Suppl):S15-9. PubMed ID: 12762289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Behrens GM
    N Engl J Med; 2005 Apr; 352(16):1721-2; author reply 1721-2. PubMed ID: 15843678
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid abnormalities.
    Dube M; Fenton M
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S79-83. PubMed ID: 12652375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
    Fodor JG; Frohlich JJ; Genest JJ; McPherson PR
    CMAJ; 2000 May; 162(10):1441-7. PubMed ID: 10834048
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving lipid goal attainment: is it enough?
    Gotto AM
    Circulation; 2009 Jul; 120(1):3-5. PubMed ID: 19546383
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV protease inhibitors and dyslipidemia.
    Clotet B; Negredo E
    AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
    Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
    Am J Kidney Dis; 2003 Apr; 41(4 Suppl 3):I-IV, S1-91. PubMed ID: 12671933
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing dyslipidaemia: current concepts.
    Schachter M
    Practitioner; 2002 Jul; 246(1636):496-9. PubMed ID: 12132267
    [No Abstract]   [Full Text] [Related]  

  • 13. Preventive efficacy of nutritional counseling.
    Kannel WB
    Arch Intern Med; 1996 Jun; 156(11):1138-9. PubMed ID: 8639007
    [No Abstract]   [Full Text] [Related]  

  • 14. Complications and side effects. Crestor tested in PHAs.
    TreatmentUpdate; 2005; 17(4):6-7. PubMed ID: 17230630
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guidelines of the Spanish Society of Nephrology: the kidney and cardiovascular disease. Short version].
    Marín R; Goicoechea MA; Gorostidi M; Cases A; Díez J; Escolar G; Fernández-Vega F; Palomar R; Rodrigo E; Martínez I; Segura J;
    Nefrologia; 2006; 26(1):31-44. PubMed ID: 16649424
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia.
    Kannel WB; Giordano M
    Am J Cardiol; 2004 Oct; 94(7):901-6. PubMed ID: 15464673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Kidney diseases associated with hyperlipidemia and its treatment].
    Aitio ML
    Duodecim; 1991; 107(16):1315-22. PubMed ID: 1365353
    [No Abstract]   [Full Text] [Related]  

  • 19. [Relationship between cardiovascular diseases and hyperlipemia. Benefits of hypolipemic therapy].
    Daubresse JC; Luyckx A
    Brux Med; 1977 Nov; 57(11):491-7. PubMed ID: 336160
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
    Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
    Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.